Zhejiang Sunflower Great Health Co., Ltd. engages in the research, development, production, and sale of anti-infectious, cardiovascular, digestive system and other drugs worldwide. It offers clarithromycin API and tablets, an anti-infective drug used for nasopharyngeal infection, lower respiratory tract infection, skin and soft tissue infection, acute otitis media, mycoplasma pneumoniae pneumonia, urethritis and cervicitis, as well as acute pharyngitis and acute tonsillitis; and azithromycin dispersible tablets for sinusitis, acute otitis media, acute bronchitis, acute exacerbation of chronic bronchitis, streptococcus pneumoniae, pneumonia, haemophilus influenzae, mycoplasma pneumoniae, urethritis, cervicitis and skin and soft tissue infection. The company also provides roxithromycin capsules to treat otitis, acute bronchitis, acute exacerbation of chronic bronchitis, pneumonia caused by mycoplasma pneumoniae or chlamydia pneumoniae, urethritis, cervicitis, and skin and soft tissue infection. In addition, it offers lacidipine dispersible tablets for treatment of hypertension; and simvastatin tablets used for pediatric patients, cholesterol, Lipoprotein B, and triglycerides. Further, the company provides omeprazole sodium for injection, a digestive system drug, used as an alternative therapy for duodenal ulcer, gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome; and famotidine for injection for treatment of peptic ulcer bleeding, acute gastric mucosal damage, and gastrointestinal bleeding caused by non-steroidal anti-inflammatory drugs. The company was formerly known as Zhejiang Sunflower Great Health Limited Liability Company and changed its name to Zhejiang Sunflower Great Health Co., Ltd. in December 2023. Zhejiang Sunflower Great Health Co., Ltd. was founded in 2005 and is headquartered in Shaoxing, China.